Dorman Products heads into its May 15 Q1 2026 earnings call with short sellers moving notably more aggressively than they were just a month ago.
Short interest has climbed to 5.1% of free float — up 29% over the past month and 17% in the past week alone. That pace of accumulation is the standout heading into the print. Days to cover runs close to 10, meaning any covering pressure would take meaningful time to unwind. Borrow costs remain low at 0.44%, and availability in the lending market is still ample, so there is no structural squeeze risk at current levels. The ORTEX short score has drifted up to 49, nudging toward the more elevated half of the range, consistent with the directional build in short positions. The stock itself has been relatively resilient — up 9% over the past month to close at $119.52, though it slipped 1.2% on Tuesday — meaning bears are fighting against a recovering tape.
Options positioning is mildly more cautious than usual, but not alarmed. The put/call ratio is running at 0.61, modestly above its 20-day average of 0.55, a z-score of 0.83 — well short of the kind of defensive extreme (the 52-week high is 1.54) that would signal real fear ahead of results. The picture is of hedging activity, not panic. Peer stocks broadly nudged higher on the week: SMP, , and each gained 4-6%, while was flat — a mild relative underperformance that may partly explain where incremental shorts are looking.
The bull-bear debate hinges on Dorman's ability to sustain margin progress in a tariff-clouded auto parts environment. Analysts remain constructive in aggregate — the mean price target is around $152, implying roughly 27% upside from current levels, and recent actions have been confirmatory rather than directional. Barrington Research reiterated Outperform at $150 just before this week's print, while Jefferies upgraded to Buy in early March, even as it cut its target to $140. Wells Fargo trimmed its target to $140 in late February while holding Overweight. The direction of travel for targets has been modestly lower since late 2025 highs near $180-185, reflecting macro uncertainty around tariffs and auto demand — but no firm has moved to the sidelines. Consensus analyst return potential of 26% and an EV/EBITDA near 9.9x on estimated figures suggest the Street sees the current price as a buying opportunity at this valuation level, assuming execution holds.
Insider activity adds a minor counterpoint. A cluster of executive sells — including the CEO, CFO, General Counsel, and CIO — occurred in early March at prices around $116, now modestly below current levels. The transactions were small individually and are consistent with routine plan selling, but the breadth of participation across the leadership team is worth noting as context for how insiders viewed fair value at the time.
Thursday's print will test whether Dorman's Q1 revenue and margin trajectory justify the recovery rally — and whether the accelerating short interest build reflects a well-founded concern or a position that a clean beat would quickly unwind.
See the live data behind this article on ORTEX.
Open DORM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
